Loading...
Images of Suhail Nurbhai
(0 from 0 )News
Takeda Submits European Marketing Authorisation Application...
www.ots.at
treatment of essential hypertension," said Suhail Nurbhai, M.D., ...
Dynogen Presents Results of Its Positive Phase 2a IBS-c Study with...
www.finanznachrichten.de
... for IBS-c,†said Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen. “DDP733 represents a valuable opportunity ...
Shionogi opens European HQ in London - PMLiVE
www.pmlive.com
... expand the number of employees in London and has already made several key appointments, including Dr Marco Renoldi, Dr Suhail Nurbhai, Dr Mark Sampson, ...
Dynogen Announces Positive Results in Phase 2 IBS-d Study
www.finanznachrichten.de
... concept for DDP225 as a treatment for IBS-d,†commented Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen.
sorted by relevance / date